Key statistics
On Friday, Ultragenyx Pharmaceutical Inc (0LIF:LSE) closed at 23.10, 28.33% above the 52 week low of 18.00 set on Dec 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 23.10 |
| Low | 23.10 |
| Bid | -- |
| Offer | -- |
| Previous close | 22.72 |
| Average volume | 1.52k |
|---|---|
| Shares outstanding | 96.63m |
| Free float | 93.58m |
| P/E (TTM) | -- |
| Market cap | 2.26bn USD |
| EPS (TTM) | -5.83 USD |
Data delayed at least 20 minutes, as of Feb 27 2026 18:47 GMT.
More ▼
- Ultragenyx to Participate at Investor Conferences in March
- Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
- Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
- Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
- Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
More ▼
